KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Common Equity (2016 - 2025)

Historic Common Equity for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $582.5 million.

  • Emergent BioSolutions' Common Equity rose 1457.51% to $582.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $582.5 million, marking a year-over-year increase of 1457.51%. This contributed to the annual value of $482.8 million for FY2024, which is 2564.3% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Common Equity is $582.5 million, which was up 1457.51% from $536.2 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Common Equity registered a high of $1.6 billion during Q4 2021, and its lowest value of $386.3 million during Q2 2024.
  • Its 5-year average for Common Equity is $1.0 billion, with a median of $957.7 million in 2023.
  • As far as peak fluctuations go, Emergent BioSolutions' Common Equity surged by 4168.22% in 2021, and later plummeted by 5966.38% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Common Equity (Quarter) stood at $1.6 billion in 2021, then decreased by 13.89% to $1.4 billion in 2022, then plummeted by 53.21% to $649.3 million in 2023, then fell by 25.64% to $482.8 million in 2024, then rose by 20.65% to $582.5 million in 2025.
  • Its last three reported values are $582.5 million in Q3 2025, $536.2 million for Q2 2025, and $552.7 million during Q1 2025.